Henry Okafor, MD
Urogynecology and Reconstructive Pelvic Surgery · Chattanooga, TNNPI 1225263254
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Axonics, Inc. at 54.4% of the total. Reporting peaked in 2021 at $5,022 and has fallen 61.9% since, to $1,914 in 2025.
Across 146 payments — averaging $87.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$7K
- Boston Scientific$2K
- Coloplast$1K
- C. R. Bard, Inc. & Subsidiaries$597
- Medtronic$532
- Procept Biorobotics Corporation$183
- plus $1K from 21 others
What the payments were for
- Consulting fees$3,15025%
- Speaking & faculty fees$2582%
- Travel & lodging$2,45719%
- Food & beverage$6,86554%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 45 | $6,937 |
| Boston Scientific | 28 | $1,976 |
| Coloplast | 14 | $1,092 |
| C. R. Bard, Inc. & Subsidiaries | 19 | $597 |
| Medtronic(2 entities) | 8 | $532 |
| Procept Biorobotics Corporation | 1 | $183 |
| Novo Nordisk | 2 | $155 |
| Urogen Pharma, Inc. | 1 | $125 |
| Endo Pharmaceuticals Inc. | 1 | $123 |
| SRS Medical Systems, Inc. | 1 | $118 |
| Neotract Inc. | 1 | $113 |
| Cook Medical LLC | 1 | $105 |
| Contura, Inc. | 2 | $104 |
| Astellas Pharma US Inc | 6 | $102 |
| Amniox Medical, Inc. | 1 | $96 |
| Calyxo, Inc. | 1 | $88 |
| Teleflex LLC | 1 | $67 |
| AbbVie(2 entities) | 4 | $65 |
| Profound Medical Corp. | 1 | $30 |
| Dentsply IH AB | 1 | $20 |
| ABC Home Medical Supply, Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Olympus America Inc. | 1 | $18 |
| Sagent Pharmaceuticals | 1 | $17 |
| Urovant Sciences Inc | 1 | $15 |
| Hollister Incorporated | 1 | $14 |
| Therapeuticsmd, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics r-SNM System$3,880
- Axonics$2,459
- Bulkamid$2,236
- ALTIS$480
- TITAN$314
- LithoVue$265
- INTERSTIM ICON$200
- AquaBeam Robotic System$183
- Tria Firm$175
- INTERSTIM$154
- rezum Generator$137
- JELMYTO$125
- XIAFLEX$123
- REZUM$121
- GENERAL FEMALE SUI$121
- UroCuff$118
- UroLift$113
- Cook$105
How this compares
$12,742 in reported general payments places this provider in the 70th percentile of 24 urogynecology and reconstructive pelvic surgery providers in Tennessee.
See all urogynecology and reconstructive pelvic surgery providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 165 | $110,580 |
| MyrbetriqMirabegron | 165 | $106,710 |
| Estradiol | 157 | $11,599 |
| Trospium Chloride ErTrospium Chloride | 70 | $11,408 |
| Solifenacin Succinate | 157 | $8,733 |
| Methenamine Hippurate | 68 | $4,000 |
| Oxybutynin Chloride ErOxybutynin Chloride | 123 | $2,862 |
| NitrofurantoinNitrofurantoin Macrocrystal | 44 | $1,820 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 29 | $1,611 |
| Trospium Chloride | 16 | $1,300 |
| Tamsulosin Hcl | 91 | $889 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 68 | $818 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 37 | $317 |
| Doxycycline Hyclate | 15 | $261 |
| CefuroximeCefuroxime Axetil | 23 | $219 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $19 | $110,580165 claims |
| Astellas Pharma US IncMyrbetriq | $102 | $106,710165 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 24 urogynecology and reconstructive pelvic surgery providers in Tennessee.
Other urogynecology and reconstructive pelvic surgery in Chattanooga
- Carson KaeserChattanooga$10K
- Tara AllenNashville$100K
- Barry JarnaginFranklin$57K
- C BowlingKnoxville$52K
- Rena AzarSouth Pittsburg$23K
- Marcy AbelNashville$22K
- Roland HuffakerJohnson City$17K
- Jeffrey McQuearyBristol$9K
- Val VogtGermantown$6K
- Jill DanfordNashville$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.